The effect of metabolic comorbidities and commonly used drugs on the prognosis of patients with ovarian cancer

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 207, Issue , 2016, Pages 227-231

  Bar, Daniel ^a   Lavie, Ofer ^a,b   Stein, Nili ^a   Feferkorn, Ido ^a   Shai, Ayelet ^c,d  

^a Department of Anesthesiology Critical Care and Pain Medicine   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c WESTERN GALILEE HOSPITAL   (Israel)

^d BAR ILAN UNIVERSITY   (Israel)

Author keywords

Aspirin; Diabetes; Hypertension; Metabolic syndrome; Ovarian cancer; Statins

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG USE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; AGED; CANCER CENTER; CANCER STAGING; CHEMICALLY INDUCED; COHORT ANALYSIS; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FOLLOW UP; ISRAEL; MIDDLE AGED; OVARIAN NEOPLASMS; OVARY; PATHOLOGY; PREVENTION AND CONTROL; PROGNOSIS; RISK FACTOR; SURGERY; SURVIVAL ANALYSIS; TUMOR RECURRENCE;

AGED; ANTIHYPERTENSIVE AGENTS; CANCER CARE FACILITIES; COHORT STUDIES; COMBINED MODALITY THERAPY; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; ISRAEL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARY; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 85003544963     PISSN: 03012115     EISSN: 18727654     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2016.09.005     Document Type: Article

References (27)

1. [1] Emerging Risk Factors Collaboration, Seshasai, S.R., Kaptoge, S., et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364 (2011), 829–841.
2. [2] Ko, E.M., Walter, P., Clark, L., et al. The complex triad of obesity, diabetes and race in type I and II endometrial cancers: prevalence and prognostic significance. Gynecol Oncol 133 (2014), 28–32.
3. [3] Ewertz, M., Jensen, M.B., Gunnarsdottir, K.A., et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol 29 (2011), 25–31.
4. [4] Jiralerspong, S., Kim, E.S., Dong, W., et al. Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients. Ann Oncol 24 (2013), 2506–2514.
5. [5] Yang, Y., Mauldin, P.D., Ebeling, M., et al. Effect of metabolic syndrome and its components on recurrence and survival in colon cancer patients. Cancer 119 (2013), 1512–1520.
6. [6] Nielsen, S.F., Nordestgaard, B.G., Bojesen, S.E., Statin use and reduced cancer-related mortality. N Engl J Med 367 (2012), 1792–1802.
7. [7] Poynter, J.N., Gruber, S.B., Higgins, P.D., et al. Statins and the risk of colorectal cancer. N Engl J Med 352 (2005), 2184–2192.
8. [8] Lavie, O., Pinchev, M., Rennert, H.S., et al. The effect of statins on risk and survival of gynecological malignancies. Gynecol Oncol 130 (2013), 615–619.
9. [9] Rothwell, P.M., Price, J.F., Fowkes, F.G., et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379 (2012), 1602–1612.
10. [10] Rothwell, P.M., Wilson, M., Price, J.F., et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379 (2012), 1591–1601.
11. [11] Jacobs, C.D., Chun, S.G., Yan, J., et al. Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy. Cancer Biol Ther 15 (2014), 699–706.
12. [12] Wu, J.W., Boudreau, D.M., Park, Y., et al. Commonly used diabetes and cardiovascular medications and cancer recurrence and cancer-specific mortality: a review of the literature. Expert Opin Drug Saf 13 (2014), 1071–1099.
13. [13] Zhang, Z.J., Li, S., The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 16 (2014), 707–710.
14. [14] Lemeshow, S., Sorensen, H.T., Phillips, G., et al. beta-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol Biomark Prev 20 (2011), 2273–2279.
15. [15] Diaz, E.S., Karlan, B.Y., Li, A.J., Impact of beta blockers on epithelial ovarian cancer survival. Gynecol Oncol 127 (2012), 375–378.
16. [16] Botteri, E., Munzone, E., Rotmensz, N., et al. Therapeutic effect of beta-blockers in triple-negative breast cancer postmenopausal women. Breast Cancer Res Treat 140 (2013), 567–575.
17. [17] Bakhru, A., Buckanovich, R.J., Griggs, J.J., The impact of diabetes on survival in women with ovarian cancer. Gynecol Oncol 121 (2011), 106–111.
18. [18] Romero, I.L., McCormick, A., McEwen, K.A., et al. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol 119 (2012), 61–67.
19. [19] Shah, M.M., Erickson, B.K., Matin, T., et al. Diabetes mellitus and ovarian cancer: more complex than just increasing risk. Gynecol Oncol 135 (2014), 273–277.
20. [20] Stalberg, K., Svensson, T., Lonn, S., Kieler, H., The influence of comorbidity on mortality in ovarian cancer patients. Gynecol Oncol 133 (2014), 298–303.
21. [21] Dilokthornsakul, P., Chaiyakunapruk, N., Termrungruanglert, W., et al. The effects of metformin on ovarian cancer: a systematic review. Int J Gynecol Cancer 23 (2013), 1544–1551.
22. [22] Kumar, S., Meuter, A., Thapa, P., et al. Metformin intake is associated with better survival in ovarian cancer: a case-control study. Cancer 119 (2013), 555–562.
23. [23] Trabert, B., Ness, R.B., Lo-Ciganic, W.H., et al. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst, 106, 2014, djt431.
24. [24] Chan, D.S., Vieira, A.R., Aune, D., et al. Body mass index and survival in women with breast cancer—systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 25 (2014), 1901–1914.
25. [25] Li, A.J., Elmore, R.G., Chen, I.Y., Karlan, B.Y., Serum low-density lipoprotein levels correlate with survival in advanced stage epithelial ovarian cancers. Gynecol Oncol 116 (2010), 78–81.
26. [26] Heitz, F., du Bois, A., Harter, P., et al. Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer—a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG. Gynecol Oncol 129 (2013), 463–466.
27. [27] Johannesdottir, S.A., Schmidt, M., Phillips, G., et al. Use of β-blockers and mortality following ovarian cancer diagnosis: a population-based cohort study. BMC Cancer, 13, 2013, 85.